Search filters

List of works by Giovanna Rege Cambrin

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

scientific article published on 17 November 2020

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

scientific article

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

scientific article published on 16 September 2011

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

scientific article

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

scientific article published on 06 October 2008

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

scientific article

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

scientific article

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

scientific article published on 17 December 2013

Dasatinib first-line: Multicentric Italian experience outside clinical trials

scientific article

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

scientific article published on 26 March 2008

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

scientific article published on 27 August 2016

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

scientific article published in August 2013

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

scientific article published on 10 October 2012

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

scientific article published on 01 January 2007

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

scientific article

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

scientific article published on 12 October 2009

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

scientific article published on 28 February 2019

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

scientific article published on 2 October 2017

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

scientific article published on 11 February 2009

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

scientific article published on 11 March 2016

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

scientific article published on 14 January 2009

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

scientific article

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

scientific article published in February 2009

Paulina is supported by:

About Paulina

Help